These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 33715980

  • 1. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.
    Chen RL, Wang Z, Huang P, Sun CH, Yu WY, Zhang HH, Yu CH, He JQ.
    Int Immunopharmacol; 2021 May; 94():107357. PubMed ID: 33715980
    [Abstract] [Full Text] [Related]

  • 2. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N, Guo Z, Wu X, Tian Y, Li Y, Geng Y, Yu Y.
    Respir Res; 2021 Sep 18; 22(1):248. PubMed ID: 34537072
    [Abstract] [Full Text] [Related]

  • 3. Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
    Tian W, Sun Y, Cheng Y, Ma X, Du W, Shi W, Guo Q.
    Thorac Cancer; 2021 Oct 18; 12(19):2551-2563. PubMed ID: 34469060
    [Abstract] [Full Text] [Related]

  • 4. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B, Wang R, Liu H.
    Biomed Res Int; 2021 Oct 18; 2021():6622342. PubMed ID: 34055989
    [Abstract] [Full Text] [Related]

  • 5. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L, Xu Z, Wu G, Chen X, Huang Y, Wang Y, Jiang W, Ke B.
    BMC Cancer; 2017 Feb 15; 17(1):138. PubMed ID: 28202053
    [Abstract] [Full Text] [Related]

  • 6. LncRNA SH3PXD2A-AS1 facilitates cisplatin resistance in non-small cell lung cancer by regulating FOXM1 succinylation.
    Chen Y, Wu S, Han Y, Shi H, Yuan J, Cui W.
    BMC Cancer; 2024 Jul 17; 24(1):848. PubMed ID: 39020302
    [Abstract] [Full Text] [Related]

  • 7. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
    Gao ZQ, Han BH, Sha HF, Shi ZY, Yang XH, Feng JX.
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr 17; 33(4):284-8. PubMed ID: 20646461
    [Abstract] [Full Text] [Related]

  • 8. KAT8 enhances the resistance of lung cancer cells to cisplatin by acetylation of PKM2.
    Li Z, Lu X, Zhang J, Liu T, Xu M, Liu S, Liang J.
    Anticancer Drugs; 2024 Sep 01; 35(8):732-740. PubMed ID: 38771737
    [Abstract] [Full Text] [Related]

  • 9. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H, Xie X, Wang K, Chen Q, Cai S, Liu D, Luo J, Kong J.
    Mol Cell Biochem; 2020 Dec 01; 475(1-2):63-77. PubMed ID: 32767026
    [Abstract] [Full Text] [Related]

  • 10. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
    Chen Y, Zhou H, Yang S, Su D.
    Cell Biochem Funct; 2021 Mar 01; 39(2):277-286. PubMed ID: 32815556
    [Abstract] [Full Text] [Related]

  • 11. Thyroid hormone enhances efficacy of cisplatin in lung cancer patients via down-regulating GLUT1 expression and reversing the Warburg effect.
    Fan C, Ren Y, Zhang W, Wen J, Zhang W, Lin S, Bai Y, Zheng T, Abay B, Li M, Fan L.
    Mitochondrion; 2024 Sep 01; 78():101919. PubMed ID: 38876298
    [Abstract] [Full Text] [Related]

  • 12. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
    Wang CK, Zhang Y, Zhang ZJ, Qiu QW, Cao JG, He ZM.
    Oncol Rep; 2015 Jan 01; 33(1):372-82. PubMed ID: 25394854
    [Abstract] [Full Text] [Related]

  • 13. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S, Zhao Y, Xu M, Yu X, Ke X, Gao R, Yin L.
    Anticancer Drugs; 2019 Sep 01; 30(8):838-845. PubMed ID: 31415285
    [Abstract] [Full Text] [Related]

  • 14. p32/OPA1 axis-mediated mitochondrial dynamics contributes to cisplatin resistance in non-small cell lung cancer.
    Yu CX, Peng ZQ, Wang T, Qu XH, Yang P, Huang SR, Jiang LP, Tou FF, Han XJ.
    Acta Biochim Biophys Sin (Shanghai); 2024 Jan 25; 56(1):34-43. PubMed ID: 38151998
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
    Hu Y, Hong Y, Xu Y, Liu P, Guo DH, Chen Y.
    Apoptosis; 2014 Nov 25; 19(11):1627-36. PubMed ID: 25213670
    [Abstract] [Full Text] [Related]

  • 16. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
    Cui Z, Li D, Zhao J, Chen K.
    Free Radic Biol Med; 2022 Apr 25; 183():106-124. PubMed ID: 35278641
    [Abstract] [Full Text] [Related]

  • 17. Niclosamide enhances the cytotoxic effect of cisplatin in cisplatin-resistant human lung cancer cells via suppression of lung resistance-related protein and c-myc.
    Zuo Y, Yang D, Yu Y, Xiang M, Li H, Yang J, Li J, Jiang D, Zhou H, Xu Z, Yu Z.
    Mol Med Rep; 2018 Mar 25; 17(3):3497-3502. PubMed ID: 29257330
    [Abstract] [Full Text] [Related]

  • 18. Yi-qi-yang-yin-tian-sui-fang enhances cisplatin-induced tumor eradication and inhibits interleukin-7 reduction in non-small cell lung cancer.
    Ke B, Wu X, Yang Q, Huang Y, Wang F, Gong Y, Liu J, Shi L.
    Biosci Rep; 2019 Jun 28; 39(6):. PubMed ID: 31138762
    [Abstract] [Full Text] [Related]

  • 19. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
    Li JM, Yang F, Li J, Yuan WQ, Wang H, Luo YQ.
    Med Sci Monit; 2020 Aug 07; 26():e925298. PubMed ID: 32764530
    [Abstract] [Full Text] [Related]

  • 20. Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.
    Li H, Zhu X, Zhang Y, Xiang J, Chen H.
    J Exp Clin Cancer Res; 2009 Aug 08; 28(1):110. PubMed ID: 19664237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.